A decent end to FY24: investors jittery with biopharma headwinds
31/01/25 -"During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was attributable to continued weakness in the Biopharma ..."
Pages
55
Language
English
Published on
31/01/25
You may also be interested by these reports :
06/02/25
Securitas had a robust Q4 24 with organic sales growth and improved operating margin, primarily driven by Europe and Ibero-America. In North America, ...
31/01/25
During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was ...
30/01/25
Eurofins has announced a strong close to FY24 – revenue was in line, but the EPS and FCF outperformed. However, the stock price is down 2.5% as ...
28/01/25
In an ad-hoc update, Rentokil reported Q4 FY24 organic revenue growth of 3.0% yoy, in line with market expectations. North America’s organic sales ...